Please assess the completion status of the following clinical trial:

Trial Title: A Clinical Study to Evaluate the Efficacy and Safety of LIV-GAMMA SN Inj. in ABO-Incompatible Liver Transplantation

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: SINGLE
- Phase: PHASE2
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~* Completed informed consent process~* Male or female aged ≥19 years and \<75 years~* Patients scheduled hospitalization for liver transplantation~Exclusion Criteria:~* Patients who are scheduled or have history of re-transplantation or multiorgan transplantation~* Patients receiving living donor in emergency~* Patients with Donor Specific Antibody (DSA) ≥ MFI 10,000 or Human Leukocyte Antigen (HLA) crossmatch (+) cytotoxic T-cell ≥ 1:32~* Patients with a history of biliary tract disease~* Patients who plasma exchange is forbidden (with a history of allergic or anaphylactic reaction to FFP, albumin, heparin, etc.)~* Patients with a history of specific medical conditions~  * Severe renal failure (eGFR \< 30 mL/min/1.73 m\^2 at screening)~ * Deep Vein Thrombosis (DVT) or thrombotic complications from Intravenous Immunoglobulin (IVIg) therapy~ * Cerebrovascular or cardiovascular disease (Hyperviscosity syndrome, Transient Ischemic Attack (TIA), Stroke, Thromboembolism, Unstable angina, etc.)~ * Clinical state causing secondary immunodeficiency (Leukemia, Lymphoma, Multiple myeloma, HIV infection, Chronic or Cyclic neutropenia (Absolute neutrophil \< 500/mm\^3), etc.)~ * Uncontrolled hypertension (Systolic blood pressure \> 160 mmHg or Diastolic blood pressure \> 100 mmHg)~ * Hemolytic or hemorrhagic anemia~ * Decreased cardiac functions~ * Bacterial, fungal or viral infection making liver transplantation forbidden~* Intraductal or vascular infiltration observed in patients with hepatocellular carcinoma using medical imaging before liver transplantation~* Patients metastasized to organs except for liver or diagnosed cancer except for liver cancer and squamous cell carcinoma within 5 years from screening~* Patients with sepsis~* Patients who had interventional therapy in blood vessels (hepatic vein, portal vein, hepatic artery, etc.) or bile ducts before LDLT~* Patients who have allergy or hypersensitivity to blood products, blood-derived products, IVIg or immunoglobulin G (IgG) products~* Patients who have immunoglobulin A (IgA) deficiency or anti-IgA antibody~* Patients who are pregnant and nursing~* Patients unwilling to use adequate method of contraception (hormonal methods, intrauterine device or intrauterine system, vasectomy, tubal ligation, etc.) during this study~* Patients who had received other investigational products within 8 weeks from complete consent or who are scheduled to receive other investigational products during this study~* Others whom the investigator considers ineligible for the study.

- Gender: ALL
- Minimum Age: 19 Years
- Maximum Age: 75 Years
- Healthy Volunteers: f

Study Arms:
- Treatment group (Type: EXPERIMENTAL): LIV-GAMMA SN Inj. administration after ABO-incompatible liver transplantation
- Comparator group (Type: OTHER): No administration after ABO-incompatible liver transplantation
- Reference group (Type: OTHER): No administration after ABO-compatible liver transplantation

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: feasibility